RESERO BIO, INC.

REQUEST FOR APPLICATIONS (RFA)

Cell-free RNA Profiling of Genitourinary Cancers using Archival Urine Supernatant Specimens

Issued: October 5, 2026

1. Overview

Resero Bio, Inc. ("**Resero Bio**") invites applications from qualifying physicians and researchers affiliated with an eligible institution to participate in a collaborative research program evaluating urine cell-free RNA (cfRNA) profiling, using Resero Bio's proprietary RARE-seq platform, in patients with genitourinary malignancies, such as bladder, prostate, and kidney cancer.

Awardees will receive Resero Bio's RARE-seq assay run on their qualifying archival urine supernatant specimens entirely on an in-kind basis. No payment will be made by or to either party under this program. Resero Bio will provide RARE-seq results to awardees, and awardees will provide access to eligible de-identified archival biospecimens and their associated clinical and demographic data pursuant to a Material Transfer Agreement, subject to the terms in Section 8.

2. Background

Resero Bio has developed a proprietary cancer detection assay and transcriptomic discovery platform incorporating RARE-seq technology (Nesselbush et al., *Nature*, 2025). RARE-seq uses a hybrid-capture, next-generation sequencing approach to quantify cfRNA gene expression, enabling sensitive and specific characterization of cancer-associated transcriptional signatures and monitoring dynamic changes in gene expression signatures over time.

3. Scientific Scope

This RFA seeks archival urine supernatant specimens (with sediment removed) from patients with genitourinary malignancies that are suitable for profiling cell-free RNA (cfRNA) dynamics over time. Particular consideration will be given to specimens collected from patients with bladder cancer receiving standard-of-care (SOC) therapy at the timepoints below. Applications proposing alternative study designs or cohorts involving investigational therapies are also welcome and will be considered.

Non-muscle invasive bladder cancer (NMIBC) cohorts. Archival urine specimens from patients with NMIBC collected longitudinally at one or more of the following timepoints:

- Pre-TURBT (baseline)
- Post-TURBT / pre-intravesical therapy
- At time of surveillance cystoscopies

Muscle-invasive bladder cancer (MIBC) cohorts. Archival urine specimens from patients with MIBC collected at one or more of the following timepoints:

- Pre-neoadjuvant treatment (EV+P or other systemic therapy)
- Post-neoadjuvant treatment / pre-cystectomy

Samples will be analyzed in batches and this RFA does not support prospective testing with real-time reporting.

4. Eligibility Criteria

To be eligible, an applicant must be a physician or researcher affiliated with an eligible institution. Additional eligibility criteria include:

1. **Patient cohort.** Cohort of archival de-identified urine supernatant specimens from patients with genitourinary malignancies.
2. **Sample collection and storage.** Archival urine supernatant specimens collected using methods compatible with Resero Bio's assay. Urine samples are suitable if collected with or without preservative and processed on the day of collection, or if collected with preservative and stored at room temperature for up to 2 days before processing. Preservatives may include EDTA, Norgen Urine Stabilizer, or Streck® Urine Preserve. Samples should be centrifuged to remove urine sediment and frozen at −80°C and not have undergone freeze-thaw cycles prior to shipment. Alternative methods for sample collection and processing may be proposed and are subject to Resero Bio's prior approval.
3. **De-identified data.** The ability to provide the associated and de-identified clinical, demographic, and longitudinal follow-up data.
4. **Regulatory.** Existing Institutional Review Board (IRB) approval (or the ability to obtain one prior to award execution) that covers the storage and external, de-identified sharing of the specimens and clinical data described in this RFA, under adequate informed consent obtained at the time of collection (or an IRB-approved waiver of consent), for the purposes described herein.
5. **Institutional eligibility.** The applicant's institution must be a non-profit academic medical center, NCI-designated cancer center, university, or non-profit hospital system that maintains an active Institutional Review Board or uses an appropriate external IRB of record. Applicants unaffiliated with such an institution, or applying independent of institutional sponsorship, are not eligible.

5. What Resero Bio Provides (In-Kind)

Resero Bio provides, at its own expense:

- RARE-seq assay processing of qualifying urine supernatant samples;
- RARE-seq assay outputs, which will be adapted to the research question, such as cancer detection scores, treatment response prediction scores, etc;
- All associated laboratory processing, sequencing, bioinformatics, data management, and project management costs.

6. What Applicants Provide

Awardees provide, at no cost to Resero Bio:

- Access to the qualifying urine supernatant specimens;
- De-identified demographic, clinical, sample-characteristic, and clinical-outcomes data;
- Confirmation of IRB approval and consent (or waiver) coverage as described in Section 4(4).

7. Application Requirements

Applications should be submitted using the form attached, including:

1. Applicant name, title, and contact information;
2. Institution name, address;
3. A brief statement of scientific interest;
4. A description of the patient cohort, including approximate cohort size, indication, treatment regimen(s), and clinical data available;
5. A description of sample collection and storage practices for the relevant timepoints;
6. Any relevant prior publications or preliminary data, if available.

Submission: Applications should be submitted to rfa@reserobio.com.

Review criteria: Applications will be evaluated on (i) fit with the eligibility criteria in Section 4; (ii) cohort quality and size, and availability of clinical outcomes data; and (iii) scientific merit and strategic fit with Resero Bio's research priorities.

Number of awards: The number of awards made under this RFA is not fixed in advance and will depend on Resero Bio's assay processing capacity and research priorities. Resero Bio may make awards at its sole discretion.

Timeline: Applications will be accepted on a rolling basis beginning **October 5, 2026**. Resero Bio anticipates completing initial review within 1 month of receipt of a complete application.

8. Required Terms for In-Kind Testing Support

As a condition of receiving in-kind RARE-seq testing support under this RFA, applicant institutions and their investigators agree to the following terms, which will be reflected in the Material Transfer Agreement described in Section 9:

- **Joint publication rights.** Resero Bio and the applicant investigator(s) will work collaboratively to analyze the Project results and prepare a joint manuscript for publication. Authorship will reflect each party's contributions to the work, consistent with standard academic authorship practices.
- **Academic-industry standard IP terms.** Ownership of intellectual property arising from the Project will follow inventorship: intellectual property solely invented by one party will be solely owned by that party, and intellectual property jointly invented by both parties will be jointly owned.
- **Residual samples and derivatives.** Resero Bio may use any leftover biological materials and any modifications for its own research and development purposes.
- **Clinical outcomes data.** Resero Bio will have access to the de-identified clinical outcomes data associated with any patient samples it analyzes under the Project and may use that data for its own research, development, and regulatory purposes.

Institutional requirements may preclude an applicant from meeting all of the above criteria. These criteria are provided at the time of application so that investigators can confirm compatibility with their institution's policies in parallel with Resero Bio's review, to help avoid delays or issues should the proposal be approved. By submitting an application, the investigator acknowledges that the above criteria must be satisfied to receive in-kind testing support under this RFA.

9. Award Process and Required Agreements

A notice of award under this RFA is **not** a binding agreement to transfer samples or data. Before any specimens or data are transferred, Resero Bio and the awardee institution will execute a Material Transfer Agreement (MTA), governing the transfer of biological materials and associated data, including the awardee's representations regarding IRB approval, informed consent (or waiver), and de-identification, ownership of the results, ownership of the underlying materials, permitted use, confidentiality, publication rights, and related terms.

A draft MTA will be provided to the awardee promptly following notice of award and is intended to be substantially in the form of Resero Bio's standard templates for this RFA, subject to good-faith negotiation of institution-specific terms.

10. Confidentiality

Applications will be treated as confidential by Resero Bio and used solely for purposes of evaluating this RFA, except as required by law. Applicants should avoid including any Confidential Information belonging to third parties in their applications.

11. Contact

Questions regarding this RFA may be directed to: rfa@reserobio.com